Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Ascelia Pharma, Audiocast, Q2'26

By Inderes8/20/2026, 8:00 AM
Ascelia Pharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Magnus Corfitzen
00:00 - 04:06

Thank you and welcome, everyone, to the webcast for Ascelia Pharma's Q2 report for 2027. On this call, we will be making forward-looking statements. On today's call, we will start with an overview of Ascelia Pharma and recent key events, and then head into our portfolio update with an emphasis on the recent Complete Response Letter for Orviglance before moving to financials and priorities ahead. After the presentation, we will open the floor for questions. At Ascelia Pharma, we identify, develop, and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We are based in Malmö, Sweden, and we are listed on Nasdaq Stockholm. We have two drugs in our pipeline. Orviglance is a diagnostic drug, and we have submitted a new drug application to the FDA to obtain approval in the US. We received a Complete Response Letter in early July and will meet with the FDA on September 9th to find the path to approval. Oncoral is a patented tablet formulation of irinotecan, with encouraging results in phase 1 and the potential to treat a range of solid tumors. In April, we raised 20 million Swedish kronor in a directed share issue, and in May, we held our annual general meeting as usual. In June, Orviglance data was presented at the ESGAR conference, the major European conference for Gastrointestinal and Abdominal Radiology. At the end of the quarter, we filed a patent application regarding packaging and manufacturing, and thus further strengthened the IP position of Orviglance. After the end of the second quarter, we received a Complete Response Letter from the FDA regarding our new drug application submission for Orviglance. This was unexpected, and we will talk more about it later in this call. We also announced that our Chief Financial Officer, Anton Hansson, will be leaving Ascelia Pharma and that we have implemented cost reductions. We have implemented cost reduction actions to improve our financial flexibility. I'd like to thank Anton for his contributions and wish him the best of luck going forward. We will start the portfolio section of our presentation with Orviglance. Despite the setback with the Complete Response Letter, we continue to be excited by Orviglance and here is why. Orviglance is addressing a well-defined unmet medical need for a subgroup of people living with cancer. This is an $800 million global addressable market opportunity, with Orviglance as a first-in-class product to target this, and the product has orphan drug designation from the FDA. We have not. We have commercial-scale manufacturing in place, and we have strong data from nine clinical studies, including compelling phase three data. As mentioned, the Orviglance new drug application has been submitted to the FDA and undergone the review process. Unfortunately, the FDA sent a Complete Response Letter with some specific issues, but many areas of the new drug application were reviewed that did not result in issues being raised. Our focus is on agreeing with the FDA on what is required to obtain approval for Orviglance. Orviglance is an attractive asset, and we will work with a partner who will drive the commercialization once the product is approved. Based on the NDA submission and the data, we remain confident in the clinical profile of the product. The unmet medical need that Orviglance addresses. The progress of the review process, including the audits conducted. We were expecting an approval of Orviglance in July. In the Complete Response Letter, the FDA raised some issues that we will discuss with them at a Type A meeting in September, so we can find an efficient path forward for Orviglance. We continue to be confident that the Orviglance new drug application is supported by substantial evidence of efficacy and safety for its intended patient population, which we think should support approval, and we are committed to bringing Orviglance to patients. We will now go into more details on the regulatory process, and I would like to hand over to Andreas.

Andreas Norlin
04:08 - 07:55

Thank you. Magnus. Yes. Magnus just mentioned receiving the Complete Response Letter was not the outcome we expected, given the interactions we had with the FDA throughout the development and the review process. And the questions in the Complete Response Letter relate primarily to aspects of the image read methodology, including the justification of the reread and interpretation of the results, together with comments on the product quality. Importantly, this gives us a focused set of issues to work through rather than a broad challenge to the overall program. Our team has moved quickly to analyze the FDA feedback and evaluate the most appropriate path forward, which we have outlined in the Type A meeting briefing package submitted to the FDA. And we continue to believe strongly in the clinical value of the product and are fully committed to addressing the agency's questions in a collaborative manner. So let me now briefly explain how we view these topics. First, I want to acknowledge that the FDA's conclusion differs from our own assessment of the data. The agency has requested additional clinical evidence, and we take that conclusion very seriously. At the same time, after extensive internal review and consultation with external experts, we continue to believe that there is a strong scientific rationale supporting the decisions that were made in the NDA application originally. Specifically, we believe that the image reread was justified by the systematic bias of the image scoring that was identified. We also believe that the training of the new readers was appropriate and that the assessment of T1-weighted images represents a clinically relevant measure of efficacy for a T1-enhancing contrast agent, such as Orviglance. The discussion around T1 can sound highly technical, but the principle is actually quite simple. Liver MRI relies on multiple imaging sequences, each contributing different and complementary information. T1 is the sequence where Orviglance is designed to work. T2 and diffusion-weighted imaging remain important parts of the examination, but they provide different types of diagnostic information. So based on this, we believe there is a strong scientific rationale for evaluating lesion visualization using T1-weighted images when assessing the effect of a T1-enhancing contrast agent. At the same time, we recognize that the FDA has taken a different view, and we remain committed to maintaining an open and constructive dialogue with the agency as we work toward the most appropriate path forward. Regarding product quality, we have aligned with the FDA's recommendations and implemented the requested actions related to product specifications. So, let me conclude by putting this into perspective. The FDA inspections carried out during the review were completed without critical findings. For the NDA, the product quality observations have been addressed in alignment with the agency's recommendations. This is highly reassuring for the continued dialogue with the FDA. The remaining discussion is centered on the interpretation of the clinical imaging data, and the upcoming Type A meeting provides an important opportunity to align with the FDA on the path forward. While we are disappointed by the outcome of the review, our confidence in Orviglance remains unchanged, and we continue to believe that the totality of the imaging, efficacy, and safety data supports approval, and we remain fully committed to bringing Orviglance to patients. So Magnus.

Magnus Corfitzen
07:55 - 09:08

Yeah. Thank you, Andreas. So I'd like to round off the Orviglance part of the presentation with some important milestones ahead. As just described, we have the Type A meeting with the FDA on September 9th, and minutes from this meeting will be available no later than 30 days after the meeting. We will provide an update once we receive the minutes. The commercial opportunity for Orviglance is attractive, with a global addressable opportunity of $800 million and almost half of that in the US. We have market exclusivity through the Orphan Drug designation and have expanded the IP position through several patent filings. The potential partners for Orviglance have confirmed continued interest in Orviglance after the receipt of the Complete Response Letter, and getting clarity on the path ahead is important for getting the partnership agreement in place. The Complete Response Letter was unexpected. We think the Orviglance data package should support approval and are committed to working with the FDA to obtain approval, as well as securing a partnership with a larger company to drive commercialization and ensure patients who will benefit from Orviglance receive it. Now we move to Oncoral. Andreas, please go ahead and address.

Andreas Norlin
09:08 - 13:31

Yes, thank you again. So while our primary focus right now is, of course, on securing a successful approval and partnering for Orviglance, we also have Oncoral in our portfolio. And that program remains an important asset. And we are looking forward to re-initiation when the timing is right. But let's just spend a few minutes on Oncoral now. Oncoral is designed to transform the delivery of irinotecan, a well-established chemotherapy that today is administered intravenously at a relatively high dose every week or every few weeks. By enabling daily oral dosing, Oncoral has the potential to provide more sustained drug exposure, improving both efficacy and tolerability, while offering a more convenient treatment option for patients. What makes Oncoral particularly interesting is that it is not simply an oral version of irinotecan. The oral formulation enables a fundamentally different treatment paradigm. Conventional irinotecan is administered as an intermittent high-dose therapy, resulting in high peak drug concentrations followed by extended periods with little or no exposure. In contrast, Oncoral is designed for daily low-dose administration, providing a more sustained exposure profile over time. Importantly, this sustained exposure may do more than simply kill tumor cells directly. A growing body of evidence suggests that metronomic chemotherapy, or daily dosing, can also influence the tumor microenvironment through mechanisms such as anti-angiogenic activity and immune modulation. As a result, Oncoral has the potential to combine the well-established anti-tumor activity of irinotecan with additional biological effects that are difficult to achieve using conventional high-dose intermittent treatment. So taken together, we believe Oncoral represents an opportunity not just to improve the delivery of irinotecan, but potentially to expand the therapeutic potential of the drug. We increasingly view Oncoral as more than an oral irinotecan formulation. It is a platform for optimizing how irinotecan is dosed. The emergence of FDA's Project Optimus reflects a broader shift in oncology from pursuing the highest tolerable dose toward identifying the dose that delivers the best balance of efficacy, safety, and long-term treatment benefit. Oncoral is inherently designed around that concept by enabling sustained daily dosing. We aim to unlock the therapeutic potential of irinotecan in a way that may improve tolerability while maintaining or potentially enhancing efficacy. Our Phase 1 data provides early validation of this approach, demonstrating a pharmacokinetic profile suitable for metronomic dosing together with encouraging safety observations. Our current plan is to bring Oncoral into clinical phase two in gastric cancer. Animal data has demonstrated a synergistic effect of irinotecan when combined with Lonsurf, another oral cancer treatment already approved for gastric cancer, which makes this all-oral combination very interesting. As we look ahead, it is important to remember that Oncoral is built on irinotecan, a well-established and widely used drug in oncology. Gastric cancer is our lead indication and represents a significant commercial opportunity in its own right. But the real strategic value lies in the potential applicability of the Oncoral dosing concept across multiple tumor types. Where irinotecan is already clinically validated, we are actively evaluating these opportunities as part of our development strategy and believe we have only begun to explore the full potential of the program. In short, we are not just developing a new formulation of irinotecan. We are developing a new way of using irinotecan with the potential to create value across multiple cancer indications. Let's move on to the update of the financials. Anton.

Anton Hansson
13:31 - 14:21

Thank you. Andreas. Thank you to. Our operating results amounted to a loss of 12 million Swedish kronor, and the costs are lower in the quarter compared to Q2 2025 due to the completion of the NDA. If we move to the liquidity at the end of June, we had a cash position of 38 million. And in April, we completed a directed share issue, raising 20 million kronor before costs. Following the Complete Response Letter, we implemented cost-saving measures and have now extended our cash runway into Q2 2027. I will now hand over to Magnus again.

Magnus Corfitzen
14:21 - 15:07

Thank you, Anton. We have some important milestones ahead. On September 9th, we will meet with the FDA to align on the path forward for Orviglance. The potential partners have confirmed continued interest in Orviglance, and getting clarity on the path ahead is important for securing a partnership agreement. We manage our finances carefully, as always, through cost reduction initiatives. We have extended the cash runway into Q2 2027. We are not where we hoped to be at this point. We have a clear plan, clear inflection points, and there continues to be an attractive opportunity for Orviglance, and we are committed to bringing Orviglance to the patients who need it. Thank you for listening to our Q2 update. The operator would now like to open the floor for questions.

Operator
15:09 - 15:28

If you wish to ask a question, please dial the pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from George Burke from ABG Sundal Collier. Please go ahead.

Unknown 1
15:31 - 16:09

Thank you. Hi, this is George from ABG. Um, yeah. So I am wondering regarding this CRL, which is obviously very important these days. To what extent has the design of T1 versus T2 weighted MRI been significant in discussions of the CRL? And I am also wondering if you are able to provide any flavor on what you are hearing from your industry contacts regarding this aftermath. Thank you.

Magnus Corfitzen
16:12 - 17:17

Maybe I can start on the partnering, and then Andreas can talk about the T1 and T2. So on the partnering, as we said, we have an ongoing process. We have been having a lot of dialogue with a number of companies, as everybody was expecting an approval, and this is a bump in the road in that dialogue. We are meeting with the FDA to get clarity on the path ahead, and that information is going to be important for the partners. So, there is still a process. But the timeline has obviously shifted a little bit because everybody wants to understand how we can resolve these issues. Which I think is important. So I think it's a very natural process. I am happy that the potential partners who have invested time, energy, and resources into evaluating the asset continue to be interested. So, Andreas, do you want to talk about the T1 and T2 sequences?

Andreas Norlin
17:17 - 18:17

Yes, absolutely. I think the question was if we have had any interactions around this with the agency through the development or the review, and as we have said, we are quite surprised by the response we received. So that indicates that we have not had any questions about that? When we talk to our advisors and key opinion leaders in the field of radiology, it's quite clear, as I tried to explain in the presentation, that the different sequences are indeed complementary to each other. So that means that you need them all. As a radiologist, when evaluating a T1 enhancing agent, it is the T1 sequence that is the scientifically most relevant sequence to look at, or the only relevant sequence to look at. I hope that was an answer to your question.

Magnus Corfitzen
18:17 - 18:51

And just to clarify, to provide some context. The gadolinium products on the market today. They also enhance T1. And like Orviglance, they do not have an effect on T2 or diffusion-weighted imaging. So, it is not an unusual thing after dosing with Orviglance. When you look at the T2 and diffusion-weighted images. That is, those images are similar between unenhanced and Orviglance. So it is not like we are making any changes to that. We are measuring where there is an expected difference based on the mechanism. And that is the relevant sequence.

Unknown 1
18:55 - 18:56

Great. Thank you.

Operator
19:01 - 19:04

The next question comes from Fredrik Tholén from Redeye. Please go ahead.

Unknown 1
19:07 - 19:23

Yes, hello and thank you. So one question was if this would accept a new reread with all images, would there be any difficulties in doing this from your perspective, or is it pretty straightforward, for example, when it comes to statistical power and so on.

Andreas Norlin
19:26 - 19:33

In that scenario, there would not be any issues. That is the short answer.

Magnus Corfitzen
19:33 - 19:37

Yeah. We have the images. Everything is captured. Yes.

Andreas Norlin
19:38 - 19:39

So it is straightforward.

Unknown 1
19:40 - 20:01

Got it. And also, our second point from that day was about the risk of bias in the training. And what is your interpretation of this and how can it be resolved. Do you see that it poses any risks of the FDA not accepting a review, or can it be resolved in some way?

Andreas Norlin
20:02 - 20:28

Our view is that we have full control over the process. Regarding the training process, the blinding of the readers in the rereading was appropriate. This is one of the questions we need to clarify with the agency. What exactly is it that they have a concern about? But we know that we have done what you should do to prevent biases of all sorts.

Magnus Corfitzen
20:30 - 20:50

And I think also the need for rereading in medical imaging is not unusual. It is also in the public space that, for instance, some of the gadolinium agents have been approved where a reread was an important part of the submission. Obviously, no two cases are alike, but it is not something completely out of the ordinary.

Unknown 1
20:53 - 20:55

Got it. Thank you. That is all for me.

Anton Hansson
20:57 - 20:57

Thanks, Frederick.

Operator
21:00 - 21:07

There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

Magnus Corfitzen
21:12 - 21:29

There are no written questions as of today. So, thank you everyone for joining. The Q2 report for 2026. We look forward to updating you once we receive the minutes or if anything happens before then. So thank you and have a great day.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…